BioCryst Pharmaceuticals 향후 성장

Future 기준 점검 4/6

BioCryst Pharmaceuticals은 연간 수입과 매출이 각각 49.4%와 15% 증가할 것으로 예상되고 EPS는 연간 47.1%만큼 증가할 것으로 예상됩니다.

핵심 정보

49.4%

이익 성장률

47.06%

EPS 성장률

Biotechs 이익 성장	23.1%
매출 성장률	15.0%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	30 Dec 2025

최근 향후 성장 업데이트

Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 06

BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 07

Recent updates

Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 06

BioCryst To Buy Astria: A Calculated Gamble That Is Not Without Risk

Oct 15

BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 07

ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities

May 09 ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Feb 25

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth

Feb 15

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Dec 09

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

Sep 29

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09

이익 및 매출 성장 예측

NasdaqGS:BCRX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	871	195	316	259	7
12/31/2027	721	106	171	100	8
12/31/2026	655	59	108	67	10
12/31/2025	617	30	128	76	9
9/30/2025	600	-9	48	50	N/A
6/30/2025	558	-36	16	17	N/A
3/31/2025	503	-53	-27	-26	N/A
12/31/2024	451	-89	-53	-52	N/A
9/30/2024	413	-124	-57	-56	N/A
6/30/2024	382	-146	-86	-84	N/A
3/31/2024	355	-209	-104	-101	N/A
12/31/2023	331	-227	-97	-95	N/A
9/30/2023	318	-236	-112	-110	N/A
6/30/2023	307	-243	-124	-123	N/A
3/31/2023	290	-226	-133	-132	N/A
12/31/2022	271	-247	-163	-162	N/A
9/30/2022	238	-193	-172	-170	N/A
6/30/2022	204	-210	-163	-161	N/A
3/31/2022	188	-194	-162	-159	N/A
12/31/2021	157	-184	-145	-142	N/A
9/30/2021	114	-227	-154	-152	N/A
6/30/2021	79	-214	-168	-167	N/A
3/31/2021	32	-209	-173	-173	N/A
12/31/2020	18	-183	-136	-135	N/A
9/30/2020	54	-125	-103	-103	N/A
6/30/2020	49	-116	-93	-92	N/A
3/31/2020	48	-115	-86	-86	N/A
12/31/2019	49	-109	-90	-90	N/A
9/30/2019	12	-134	-103	-103	N/A
6/30/2019	12	-126	N/A	-111	N/A
3/31/2019	23	-107	N/A	-100	N/A
12/31/2018	21	-101	N/A	-93	N/A
9/30/2018	22	-93	N/A	-79	N/A
6/30/2018	29	-79	N/A	-56	N/A
3/31/2018	20	-77	N/A	-52	N/A
12/31/2017	25	-66	N/A	-41	N/A
9/30/2017	30	-51	N/A	-36	N/A
6/30/2017	29	-47	N/A	-42	N/A
3/31/2017	31	-47	N/A	-43	N/A
12/31/2016	26	-55	N/A	-53	N/A
9/30/2016	22	-69	N/A	-62	N/A
6/30/2016	25	-72	N/A	-58	N/A
3/31/2016	46	-51	N/A	-28	N/A
12/31/2015	48	-43	N/A	-13	N/A
9/30/2015	49	-37	N/A	-12	N/A
6/30/2015	41	-31	N/A	-8	N/A
3/31/2015	17	-50	N/A	-33	N/A

애널리스트 향후 성장 전망

수입 대 저축률: BCRX 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.3%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: BCRX (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: BCRX 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: BCRX 의 수익(연간 15%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: BCRX 의 수익(연간 15%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: BCRX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/31 11:51
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

BioCryst Pharmaceuticals, Inc.는 28명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Huidong Wang	Barclays
Tazeen Ahmad	BofA Global Research
Dae Gon Ha	BTIG

BioCryst Pharmaceuticals 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Forecast breakeven date pushed back to 2026

Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 7.3% to US$17.56

BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

BioCryst Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2025

Recent updates

Forecast breakeven date pushed back to 2026

President & Chief Commercial Officer exercised options to buy US$572k worth of stock.

Biocryst Pharmaceuticals, Inc. Announces Retirement of Nancy J. Hutson, Ph.D. and Election of Vincent J. Milano as Next Chair of the Board

Senior VP recently sold US$367k worth of stock

Senior VP notifies of intention to sell stock

Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO

BioCryst Pharmaceuticals, Inc. Appoints Ron Dullinger as Chief Commercial Officer, Effective January 1, 2026

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

BioCryst Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 03, 2025

Biocryst Pharmaceuticals, Inc. Appoints Jill C. Milne to Board of Directors

BioCryst To Buy Astria: A Calculated Gamble That Is Not Without Risk

Price target increased by 7.3% to US$17.56

BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX) agreed to acquire Astria Therapeutics, Inc. (NasdaqGM:ATXS) for approximately $720 million.

BioCryst Announces Departure of Dr. Helen Thackray, Chief Research and Development Officer on September 1, 2025

BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Second quarter 2025 earnings released

BioCryst Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2025

Biocryst Pharmaceuticals, Inc. Announces CEO Changes

BioCryst Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 04, 2025

BioCryst Pharmaceuticals, Inc. Appoints Babar Ghias Chief Financial Officer

Neopharmed Gentili S.p.A. agreed to acquire Biocryst Ireland Limited from BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX) for approximately $260 million.

Biocryst Pharmaceuticals, Inc. Extends the Prescription Drug User Fee Act Goal Date for the Company's New Drug Application for the Use of Once-Daily Orladeyo (Berotralstat) Oral Granules

BioCryst Pharmaceuticals, Inc. Announces Retirement of George B. Abercrombie as A Member of the Board's Audit Committee, Commercialization Committee, and Corporate Governance and Nominating Committee, Effective June 12, 2025

Biocryst Pharmaceuticals, Inc. Presents New Data on the Long-Term Efficacy and Safety of Orladeyo®? (Berotralstat) Across All Ages At Eaaci

BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Achieves Reimbursement for ORLADEYO Across All Major European Countries

BioCryst Pharmaceuticals, Inc. to Present New Data At 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Pharmaceuticals, Inc. Highlights Real-World Data Showing ORLADEYO®? (berotralstat) Consistently Reduces HAE Attacks Across All Ages

BioCryst Announces FDA Acceptance of NDA for ORLADEYO®? (berotralstat) Oral Granules in Patients with HereditaryAngioedema Aged 2 to 11 Years

ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities

Price target increased by 13% to US$16.58

BioCryst Pharmaceuticals, Inc. Increases Financial Guidance for the Full Year 2025

First quarter 2025 earnings released: EPS: US$0 (vs US$0.17 loss in 1Q 2024)

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2025

BioCryst Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 05, 2025

Biocryst Pharmaceuticals, Inc. Appoints Jon P. Stonehouse, to Serve as Interim Principal Accounting Officer

BioCryst Pharmaceuticals, Inc. Announces Resignation of Anthony Doyle as Chief Financial Officer, Effective April 9, 2025

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Full year 2024 earnings: EPS misses analyst expectations

Biocryst Pharmaceuticals, Inc. Increases Revenue Guidance for the Year 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth

BioCryst Pharmaceuticals, Inc. Launches ORLADEYO (berotralstat) in Portugal

BioCryst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 24, 2025

BioCryst Pharmaceuticals, Inc. Provides Preliminary Unaudited Total Revenue Guidance for the Fourth Quarter and Year 2024 and Year 2025

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland

Consensus estimates of losses per share improve by 14%

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Insufficient new directors

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

Consensus estimates of losses per share improve by 41%

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Senior VP recently bought US$202k worth of stock

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price